Background: Intracranial hemorrhage (ICH) is a serious, life-threatening, but fortunately rare complication of non-vitamin K oral anticoagulant (NOAC) therapy. There are limited data on NOAC-related ICH prognosis. Methods: All consecutive patients admitted to a single center due to acute NOAC-related ICH from September 2012 until the beginning of 2017 were included. Risk factors, type of NOAC, and location of ICH were evaluated. Risk for ischemic and bleeding events and clinical status upon admission and at discharge were evaluated using standard scales. Results: Thirty-four patients aged 77.8 ± 8.3 years with NOAC-related ICH were included. The main predisposing risk factors were age and arterial hypertension. The median CHA 2 DS 2 -VASc score was 3.4 and the median HAS-BLED score was 1.8. Eighteen patients were treated with rivaroxaban, 11 with dabigatran, and 5 with apixaban. Ten patients (29%) had a favorable outcome with a modified Rankin Scale score ≤2 and 13 patients (38%) died. The location of the ICH was mainly intraparenchymal and subdural. Conclusions: Our retrospective single-center study shows that the mortality rate with NOAC-related ICH is <40%, which makes it comparable to that with vitamin K antagonist-related ICH.
Introduction
Intracranial hemorrhage (ICH) is a serious, life-threatening, but fortunately rare complication of anticoagulation therapy. For many years, vitamin K antagonists (VKA) were the only available oral anticoagulation therapy. Further on, non-vitamin K oral anticoagulants (NOAC) have been approved as a safer and more effective anticoagulant therapy compared to VKA in randomized, multicenter, clinical studies [1] [2] [3] . A meta-analysis of the initial randomized studies showed that compared to VKA, treatment with NOAC reduces overall mortality among patients with atrial fibrillation (AF) [4] . The high mortality rate was largely due to ICH. According to the initial studies, the incidence of ICH due to NOAC therapy is 0.2-0.5% per year [1] [2] [3] , compared to 0.3-0.8% per year among well-controlled VKA patients [5] . The location of ICH due to NOAC therapy is mainly intraparenchymal and subdural [6] . According to several studies, even with modern treatment approximately half of the patients with VKAassociated ICH die within 30 days [7] [8] [9] [10] [11] [12] [13] . However, data on the prognosis of patients with NOAC-related ICH are relatively scarce.
One of the main safety issues with regard to the introduction of NOAC used to be the lack of an antidote. Nevertheless, the effect of VKA is delayed and a nonspecific, rapidly acting agent -in most cases human prothrombin complex concentrate -is typically coadministered. The same agents are usually applied in NOAC patients. With the introduction of idarucizumab as a specific, instantly working antidote for dabigatran, probably the prognosis of dabigatranrelated ICH is currently improving.
There are only limited data on NOAC-related ICH prognosis. Initial studies reported a mortality rate of 52-67% [14] . With time, the results improved and the described mortality rate was 28-40%, whereas a favorable outcome was observed in 10-35% [15] [16] [17] . In a recent study, the outcome appeared to be similar to that of VKA-related ICH [17] .
Multicenter studies involving small numbers of patients from each site may not be as convincing as real-life data coming from a single center. In order to investigate the outcome and prognosis of patients with NOAC-related ICH, we therefore describe the outcomes of all consecutive patients who were admitted to the Neurology Clinic, University Clinical Center Ljubljana, since the introduction of the first NOAC in September 2012.
Methods

Study Population
The University Medical Center Ljubljana provides neurological care and hospitalization to about 1 million people who live in central Slovenia. In addition, it is the only neurological intensive care unit in Slovenia with its about 2 million inhabitants. This retrospective study was restricted to patients who were admitted to the Neurology Clinic, University Clinical Center Ljubljana, due to acute intracerebral hemorrhage related to NOAC therapy during a 4-year period from September 2012 until September 2016.
The location of the ICH was evaluated. We evaluated the type of NOAC (dabigatran, rivaroxaban, or apixaban) and the indication for NOAC prescription. In addition to general data about the patients such as age and gender, we collected data about cardiovascular risk factors (arterial hypertension, diabetes mellitus, and hyperlipidemia) as well as risk factors for bleeding events (previous stroke, renal function, liver function, and thrombocytes). We also collected data on the patients' medical treatment (additional antiaggregant treatment, statins, nonsteroidal anti-inflammatory drugs, and antidepressants). In patients who received NOAC due to AF, we calculated the CHA 2 DS 2 -VASc score [18, 19] , which predicts the risk of stroke in patients with AF, and the HAS-BLED score [18] , which predicts the risk of bleeding.
We evaluated the clinical status of the patients upon admission as well as at discharge (if applicable) using the National Institutes of Health stroke Scale (NIHSS), modified Rankin Scale (mRS), and Glasgow Coma Scale (GCS). We also collected data about the use of prothrombin complex concentrate and idarucizumab.
The study was based on a retrograde evaluation of data recorded in standard protocols of treatment; thus, no additional procedures were performed, and also no additional data were collected. Therefore, no specific ethics committee approval was sought.
Results
Thirty-four patients with acute ICH related to NOAC therapy were admitted from September 2012 until the end of September 2016. The mean age of the patients was 77.8 ± 8.3 years. There were 20 women and 14 male patients. The main characteristics of the patients are described in Table 1 . The median CHA 2 DS 2 -VASc score was 3.4 and the median HAS-BLED score was 1.8. They all had normal glomerular filtration rates and normal platelet counts, and none had liver dysfunction. The majority had arterial hypertension. None of them were concomitantly treated with nonsteroidal anti-inflammatory drugs or antiplatelet drugs. Two patients were treated with antidepressants (duloxetine and escitalopram) and 7 patients were treated with statins. None abused alcohol or illegal drugs.
Eighteen patients were treated with rivaroxaban, 11 with dabigatran, and 5 with apixaban. NOAC therapy was prescribed due to AF for all 34 patients. For 31 patients, NOAC was prescribed as primary stroke prevention. Only 3 patients received NOAC (dabigatran) as secondary stroke prevention. The locations of the hemorrhages and their prognoses are described in Table 2 . Twentysix patients suffered intraparenchymal hemorrhage, 1 intraventricular hemorrhage, 2 subarachnoid hemorrhage (SAH), 4 subdural hematoma, and 1 hemorrhagic transformation of ischemic stroke. In 4 patients, the ICH was traumatic, and the rest had a spontaneous ICH. Thirteen patients died: 8 patients with rivaroxaban-related ICH, 4 patients with dabigatranrelated ICH, and 1 patient with apixaban-related ICH.
Seventeen patients were treated with prothrombin complex concentrate and 4 patients were treated with idarucizumab. The outcomes of the patients are described in Figures 1 and  2 . Ten patients (29%) had a favorable outcome of an mRS score ≤2. Thirteen patients (38%) died. The mean mRS score at discharge among the survivors was 3.2.
A subanalysis of the 26 patients with intraparenchymal hemorrhage was also done. Nine patients were male and 17 patients were female. No one had had an ICH before, whereas 3 had suffered an ischemic stroke in the past. In 1 patient, the ICH was traumatic. Eleven patients
Number of patients
29.4% mRS ≤2
38.2% mRS 6 (40%) died: 7 with rivaroxaban-related ICH, 3 with dabigatran-related ICH, and 1 with apixaban-related ICH.
In only 2 of our patients, NOAC therapy was reinitiated. The first patient suffered traumatic intraparenchymal hemorrhage (CHA 2 DS 2 -VASc score 2; HAS-BLED score 2) and prothrombin complex was used. The patient recovered completely (NIHSS 0; mRS score 0); a control CT scan of the head 4 weeks after discharge showed complete resorption of the ICH. Prior to bleeding, the patient had been treated with rivaroxaban, and we reinitiated the same drug. The second patient suffered aneurysmal SAH (CHA 2 DS 2 -VASc score 1; HAS-BLED score 1), which was treated endovascularly. Prothrombin complex was used. The patient recovered completely (NIHSS 0; mRS score 0), and a control CT scan of the head 3 weeks after discharge showed complete reabsorption of the SAH. Prior to bleeding, the patient had been treated with apixaban, and we reinitiated the same drug.
Discussion
The main finding of our observational, retrospective, single-center study was that the mortality rate among the patients with NOAC-related ICH was 38%, whereas a favorable outcome of an mRS score ≤2 was achieved in 28% of the patients. The number of ICH increased over the years, probably due to the increasing number of patients on NOAC therapy. We noticed no decrease in mortality rate over time in spite of gaining more experience with such patients over the years and the recent availability of an antidote for dabigatran. However, due to the small number of patients, more exact conclusions on trends regarding mortality rate cannot be drawn.
Our results are similar to the results of a limited number of previous studies. A Spanish retrospective analysis from 2014 reported a very similar 40% mortality rate and a favorable outcome in only 25% of all patients [15] . A recent German prospective, multicenter, observational study of nontraumatic NOAC-related ICH reported a 28% mortality rate and a favorable outcome in 25% of the patients [16] . However, the most recent prospective multicenter study of 97 NOAC-related ICH described a 33% mortality rate and a favorable outcome in only 10% of the patients [17] .
Although the mortality rate among these patients seems high, it is important to mention that these patients most often suffer from spontaneous ICH. The mortality rate after spontaneous ICH among patients without specified antithrombotic therapy ranges from 34 to 50% [9-11, 20, 21] and 12-39% of the patients achieve independent function [20] . A subanalysis has shown that the overall mortality among 75-to 84-year-old patients with ICH without anticoagulation was 26.8% [20] . Anticoagulation therapy is associated with worse clinical outcome after ICH [9, 22] . Even a well-conducted VKA therapy in patients with AF with an international normalized ratio (INR) between 2 and 3 doubles the risk of ICH, but the mortality rate is significantly higher if the INR is above the therapeutic level. The mortality rate with VKA-associated ICH in clinical studies is up to 68% [9, 13, 23, 24] . In older patients with wellcontrolled INR, the mortality rate is 49% [11] . Thus, compared to these rates, mortality from NOAC-related ICH is relatively low. So far, there has only been one prospective study directly comparing the outcomes of NOAC-and VKA-related ICH, and there was no difference in outcome [17] .
The location of the ICH in our patients was mainly intraparenchymal (76%) and subdural (12%), which is comparable to the data from the literature [14] . The subanalysis of the intraparenchymal hemorrhages showed a similar rate of mortality to that of the whole group.
As is known from randomized, multicenter, clinical trials, the incidence of ICH among patients treated with NOAC is significantly lower than among VKA-treated patients [1] [2] [3] .
Real-life data on ICH in patients treated with NOAC are scarce. Unfortunately, we cannot draw any conclusions about the incidence of NOAC-related ICH based on our study, since the absolute number of NOAC users is not known. However, since 2012, when the first NOAC was introduced, the number of NOAC users has been increasing, and, as expected, the number of NOAC-related ICH has increased. With time, the duration of NOAC treatment for a single patient has probably also increased, and this could have influenced the increase in the incidence of ICH. Unfortunately, we do not have data about the duration of NOAC treatment for our patients and can only speculate about that.
In any case, since 2015 the number of ICH cases has remained relatively stable and the relative proportion of patients with ICH has presumably decreased. This is probably due to good patient selection. This fact is further supported by the analysis of the risk factors of the patients who suffered ICH. Our patients had a low HAS-BLED score and quite a high CHA 2 DS 2 -VASc score. In the majority of our patients, age and uncontrolled arterial hypertension were the only predisposing factors for ICH. Almost 91% of the patients with ICH had had no prior stroke or transient ischemic attack. None of them had liver or renal dysfunction. The platelet count was normal in our patients. None of the patients was concomitantly treated with antiplatelet therapy [23, 24] or nonsteroidal anti-inflammatory drugs. Two patients were taking antidepressants (escitalopram and duloxetine), which has been associated with a higher incidence of ICH when taken in combination with NOAC [25] . Twenty-one percent of our patients were concomitantly treated with statins, which could also be another predisposing factor for ICH [26, 27] . In most cases, the ICH was probably spontaneous and would have occurred with or without anticoagulant treatment.
In conclusion, we can state that the recorded mortality rate after NOAC-related ICH was 38%. The location of the ICH was mainly intraparenchymal and subdural. Twenty-nine percent of the patients had a favorable outcome of an mRS score ≤2. In spite of good selection of the patients for NOAC therapy, spontaneous ICH do occur in older patients with arterial hypertension, which remains the main predisposing risk factor.
